TY - JOUR TI - Registered report: BET bromodomain inhibition as a therapeutic strategy to target c-Myc AU - Kandela, Irawati AU - Jin, Hyun Yong AU - Owen, Katherine AU - Reproducibility Project: Cancer Biology A2 - Glass, Christopher VL - 4 PY - 2015 DA - 2015/06/25 SP - e07072 C1 - eLife 2015;4:e07072 DO - 10.7554/eLife.07072 UR - https://doi.org/10.7554/eLife.07072 AB - The Reproducibility Project: Cancer Biology seeks to address growing concerns about reproducibility in scientific research by replicating selected results from a substantial number of high-profile papers in the field of cancer biology published between 2010 and 2012. This Registered report describes the proposed replication plan of key experiments from ‘BET bromodomain inhibition as a therapeutic strategy to target c-Myc’ by Delmore and colleagues, published in Cell in 2011 (Delmore et al., 2011). The key experiments that will be replicated are those reported in Figures 3B and 7C-E. Delmore and colleagues demonstrated that treatment with JQ1, a small molecular inhibitor targeting BET bromodomains, resulted in the transcriptional down-regulation of the c-Myc oncogene in vitro (Figure 3B; Delmore et al., 2011). To assess the therapeutic efficacy of JQ1 in vivo, mice bearing multiple myeloma (MM) lesions were treated with JQ1 before evaluation for tumor burden and overall survival. JQ1 treatment significantly reduced disease burden and increased survival time (Figure 7C-E; Delmore et al., 2011). The Reproducibility Project: Cancer Biology is a collaboration between the Center for Open Science and Science Exchange and the results of the replications will be published in eLife. KW - Reproducibility Project: Cancer Biology KW - methodology KW - bromodomain inhibitor KW - myeloma KW - targeted therapy JF - eLife SN - 2050-084X PB - eLife Sciences Publications, Ltd ER -